Spire's six most recent Spirethoughts.

Drones are delivering medicine in Africa
Nigeria has entered the AFCFTA African free trade agreement, increasin...
IT investments to pour into India’s healthcare sector
The European Union-Vietnam Free Trade Agreement (EVFTA) is set to open...
Deploying Industry 4.0 technology to mitigate climate change
Deploying Industry 4.0 technology to mitigate climate change
Will cost-effective compost rejuvenate African agriculture
Will compost turn out to be the magic mineral for African agriculture?

Indian pharma industry hit by ban on FDC drugs

The Indian Pharmaceutical industry – with a market size of INR1 lakh crore (as of 2016) – faces a loss of approximately INR10,000 crore due to the unforeseen ban of 344 Fixed Dose Combination (FDC) Drugs by the government.

The ban discontinues the sale and manufacture of popular brands like Vicks Action 500 Extra – from Procter & Gamble (P&G) – a Fast-Moving Consumer Goods (FMCG), among others.

Pharma giants Abbott, Pfizer and Macleods Pharma have urged a stay or lifting of the ban. With 1,000 cases under scrutiny, the industry is bound to see more legal battles.

FDC drugs are banned in UK and the US due to health risks they pose such as anti-microbial resistance and even organ failure.

How will India’s Pharma market pick itself up from the FDC drugs ban?

For media enquiries, please contact:

Nidhi Singh
Assistant Manager, Group Corporate Communications
Spire Research and Consulting
Phone: (91) 124 646 5499
E-mail: nidhi.singh@spireresearch.com

Back to Top

Back to Home